PURPOSE: To compare @entity1073 ( @entity1073 ) and @entity706 ( @entity706 ) for their features of clinical presentation, response to chemotherapy, and prognosis on the basis of a prospective randomized clinical trial. @entity1 AND METHODS: @entity1 with @entity11708 and FCL who entered onto the prospective randomized comparison of @entity786 , @entity1891 , and @entity229 ( @entity9107 ) versus @entity42870 and @entity2664 (PmM) followed by a second randomization for interferon (IFN) maintenance versus observation only. RESULTS: One hundred sixty-five of 234 @entity1 had FCL and 45 of 234 @entity1 had @entity11708 . With FCL, both sexes were equally affected ( @entity1 , 47%); @entity1 with @entity11708 were predominantly @entity1 (78%; P < .0004) and had a higher median age (64 v 53 years; P < .0001). @entity1 with @entity11708 also had more @entity66 , reflected by the proportion of @entity1 with two or greater extranodal manifestations (43% v 21%; P < .005) and nine or greater involved nodal areas (64% v 45%; nonsignificant [NS]). Response to chemotherapy was significantly lower in @entity1 with @entity11708 (complete remission [CR] + partial remission [PR], 69% v 88%; P < .05) and occurred at a slower pace. @entity1 with @entity11708 also had a shorter event-free interval (median, 8 v 24 months; P < .0001) and overall survival (median, 28 v 77 months; P < .0001). In both subtypes, however, @entity1 with less than two residual lymphoma manifestations in remission experienced a relatively good prognosis with an estimated 5-year survival of greater than 60% for @entity11708 and greater than 75% for FCL. CONCLUSION: @entity11708 and FCL differ substantially in their features of presentation, response to chemotherapy, and long-term prognosis. The extent of @entity66 after completion of chemotherapy discriminates @entity1 with different prognosis and may be used for the stratification of postremission strategies.

XXXX have more @entity66 and a slower response to chemotherapy compared with @entity706 : results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS', 'men'] @entity9107 :: ('114769', 'Gene') :: ['COP'] @entity42870 :: ('MESH:D011238', 'Chemical') :: ['prednimustine'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease', 'widespread disease'] @entity706 :: ('MESH:D008223', 'Disease') :: ['FCLs', 'follicle-center lymphomas'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity11708 :: ('OMIM:150800', 'Disease') :: ['MCL'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['MCLs', 'mantle-cell lymphomas'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']
@entity1073 :: (MESH:D020522,Disease) :: ['Mantle-cell lymphomas']
